SlideShare a Scribd company logo
1 of 61
Download to read offline
by
Case 1
Male patient 49 y old , DM 5 years ago controlled
on insulin , not HTN,
labs of routine follow up
24 hour urinary protein 120 mg /d.
what`s the best choice ?
1. Add ACEI
2. Protein restriction
3. Follow up after 3 months
4. Assess proteinuria e different method
GN presentation
GN PRESENTING WITH NEPHROTIC SYNDROME
Minimal change GN
Membranous GN
Focal segmental GN (FSGN)
Amyloidosis
Diabetic nephropathy
GN PRESENTING WITH NEPHRITIC SYNDROME
Diffuse proliferative GN
Rapidly progressive GN (RPGN)
GN WITH NEPHROTIC SYNDROME or NEPHRITIC SYNDROME or MIXED NEPHROTIC/NEPHRITIC
Membranoproliferative GN
Mesangioproliferative GN
Nephritic syndrome
A disease characterized by acute onset of :
Proteinuria (sub nephrotic)
Hematuria… dysmorphic RBCs,RBCs cast
Oliguria
Hypertension
Odema
GN presentation
GN PRESENTING WITH NEPHROTIC SYNDROME
Minimal change GN
Membranous GN
Focal segmental GN (FSGN)
Amyloidosis
Diabetic nephropathy
GN PRESENTING WITH NEPHRITIC SYNDROME
Diffuse proliferative GN
Rapidly progressive GN (RPGN)
GN WITH NEPHROTIC SYNDROME or NEPHRITIC SYNDROME or MIXED NEPHROTIC/NEPHRITIC
Membranoproliferative GN
Mesangioproliferative GN
Proteinuria and
KDIGO
guidelines
Proteinuria and CKD
Proteinuria and
Supportive TTT
ACEi and/or ARBs lower GFR, and a 10%–20% increase in
SCr is often observed.
Unless creatinine continues to rise,
this moderate increase reflects their effect on kidney
hemodynamics
and not worsening intrinsic kidney disease, and should not
prompt withdrawal of the medication
If the patient is unable to tolerate an
ACEi or ARB
a direct renin inhibitor (DRI) or
mineralocorticoid receptor antagonist
(MRA) can be used
unable to tolerate even low-dose
ACEi, ARB, MRA, or DRI.
antihypertensive agents are recommended for both
control of BP and improvement in urine protein excretion.
&Non dihydropyridine (CCB), such as diltiazem and verapamil,
modestly reduce proteinuria.
&Beta blockers, diuretics, and a-1 blockers also reduce
proteinuria, but to a lesser degree.
&Dihydropyridine CCB and methyldopa have little impact on
proteinuria and may even increase proteinuria.
Proteinuria and anticoagulation
Bleeding Risk
Can use NOAC or not in NS?
Case 2
Female patient 48 y old, HTN on bisoprolol 5mg
,presented e lower limb edema and poly
arthropathy
labs :
24 h urinary protein 1.8 g/d
serum albumin 3.6
ANA 1/80
C3,C4 :normal
virology : -ve
Renal biopsy done
NB: F/u ANA in diff lab ANA less than 1/40
What`s the next step?
1- start steroid
2- start steroid and cyclosporine
3- supportive TTT { ACEI,…}e f/u ptnuria.albumin
4- follow up after 3 months
Proteinuria in FSGS
NB: F/u ANA in diff lab ANA less than 1/40
What`s the next step?
1- start steroid
2- start steroid and cyclosporine
3- supportive TTT { ACEI,…}e f/u ptnuria.albumin
4- follow up after 3 months
Proteinuria in IgA N
Proteinuria in Membranous
Nephropathy
Proteinuria in ICGN(MPGN)
Proteinuria in SLE
proteinuria approach Dr. Abdel Rahman Mansy.pdf
proteinuria approach Dr. Abdel Rahman Mansy.pdf
proteinuria approach Dr. Abdel Rahman Mansy.pdf
proteinuria approach Dr. Abdel Rahman Mansy.pdf

More Related Content

What's hot

Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadDiabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadNephroTube - Dr.Gawad
 
Adult Minimal Change Disease (KDIGO 2021 Guidelines)
Adult Minimal Change Disease (KDIGO 2021 Guidelines)Adult Minimal Change Disease (KDIGO 2021 Guidelines)
Adult Minimal Change Disease (KDIGO 2021 Guidelines)NephroTube - Dr.Gawad
 
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadIgA Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
 
Membranous Nephropathy
Membranous NephropathyMembranous Nephropathy
Membranous NephropathyNahid Haque
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. GawadHemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. GawadNephroTube - Dr.Gawad
 
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKDCARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKDMohd Tariq Ali
 
Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)Tauhid Bhuiyan
 
CKD (Pathogensis and Progression) - Dr. Gawad
CKD (Pathogensis and Progression) - Dr. GawadCKD (Pathogensis and Progression) - Dr. Gawad
CKD (Pathogensis and Progression) - Dr. GawadNephroTube - Dr.Gawad
 
Updates in management of membranous nephropathy - Dr. Mohammed Kamal Nassar
Updates in management of membranous nephropathy - Dr. Mohammed Kamal NassarUpdates in management of membranous nephropathy - Dr. Mohammed Kamal Nassar
Updates in management of membranous nephropathy - Dr. Mohammed Kamal NassarMNDU net
 
Diabetic nephropathy
Diabetic nephropathyDiabetic nephropathy
Diabetic nephropathyPrateek Singh
 
Diabetic Nephropathy Review
Diabetic Nephropathy ReviewDiabetic Nephropathy Review
Diabetic Nephropathy ReviewJAFAR ALSAID
 
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. Gawad
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. GawadInfection Related Glomerulopathy - Introduction – Rapid Overview - Dr. Gawad
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. GawadNephroTube - Dr.Gawad
 
Recent advancement in managing diabetic nephropathy
Recent advancement in managing diabetic nephropathyRecent advancement in managing diabetic nephropathy
Recent advancement in managing diabetic nephropathypp_shivgunde
 
Autoimmune hemolytic anemia
Autoimmune hemolytic anemiaAutoimmune hemolytic anemia
Autoimmune hemolytic anemiaDr. Hasan Osman
 
Glomerulonephritis
GlomerulonephritisGlomerulonephritis
GlomerulonephritisSimon Prince
 

What's hot (20)

Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadDiabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
 
Sickle cell nephropathy SCN
Sickle cell nephropathy SCNSickle cell nephropathy SCN
Sickle cell nephropathy SCN
 
Adult Minimal Change Disease (KDIGO 2021 Guidelines)
Adult Minimal Change Disease (KDIGO 2021 Guidelines)Adult Minimal Change Disease (KDIGO 2021 Guidelines)
Adult Minimal Change Disease (KDIGO 2021 Guidelines)
 
Diabetic+Nephropathy
Diabetic+NephropathyDiabetic+Nephropathy
Diabetic+Nephropathy
 
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadIgA Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
 
Membranous Nephropathy
Membranous NephropathyMembranous Nephropathy
Membranous Nephropathy
 
Hepatic encephalopathy
Hepatic encephalopathyHepatic encephalopathy
Hepatic encephalopathy
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. GawadHemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
 
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKDCARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
 
Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)
 
CKD (Pathogensis and Progression) - Dr. Gawad
CKD (Pathogensis and Progression) - Dr. GawadCKD (Pathogensis and Progression) - Dr. Gawad
CKD (Pathogensis and Progression) - Dr. Gawad
 
Renal vasculitis
Renal vasculitisRenal vasculitis
Renal vasculitis
 
Updates in management of membranous nephropathy - Dr. Mohammed Kamal Nassar
Updates in management of membranous nephropathy - Dr. Mohammed Kamal NassarUpdates in management of membranous nephropathy - Dr. Mohammed Kamal Nassar
Updates in management of membranous nephropathy - Dr. Mohammed Kamal Nassar
 
Diabetic nephropathy
Diabetic nephropathyDiabetic nephropathy
Diabetic nephropathy
 
Diabetic Nephropathy Review
Diabetic Nephropathy ReviewDiabetic Nephropathy Review
Diabetic Nephropathy Review
 
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. Gawad
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. GawadInfection Related Glomerulopathy - Introduction – Rapid Overview - Dr. Gawad
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. Gawad
 
Recent advancement in managing diabetic nephropathy
Recent advancement in managing diabetic nephropathyRecent advancement in managing diabetic nephropathy
Recent advancement in managing diabetic nephropathy
 
Autoimmune hemolytic anemia
Autoimmune hemolytic anemiaAutoimmune hemolytic anemia
Autoimmune hemolytic anemia
 
Glomerulonephritis
GlomerulonephritisGlomerulonephritis
Glomerulonephritis
 

Similar to proteinuria approach Dr. Abdel Rahman Mansy.pdf

NEPHROTIC SYNDROME
NEPHROTIC SYNDROMENEPHROTIC SYNDROME
NEPHROTIC SYNDROMERaman Kumar
 
nephrotic syndrome final TREATMENT EVALUATION.ppt
nephrotic syndrome final TREATMENT EVALUATION.pptnephrotic syndrome final TREATMENT EVALUATION.ppt
nephrotic syndrome final TREATMENT EVALUATION.pptBIMALESHYADAV2
 
Generalized oedema & Proteinuria
Generalized oedema & ProteinuriaGeneralized oedema & Proteinuria
Generalized oedema & ProteinuriaMohammed Musa
 
Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...
Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...
Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...FarsanaM
 
Nephrotic and nephritic Syndrome children 7.ppt
Nephrotic and nephritic Syndrome children 7.pptNephrotic and nephritic Syndrome children 7.ppt
Nephrotic and nephritic Syndrome children 7.pptArun170190
 
Nephrotic syndrome
Nephrotic syndrome Nephrotic syndrome
Nephrotic syndrome AZu SA
 
NEPHROTIC SYNDROME.pptx1236ygdsdfhjjhtgedsx
NEPHROTIC SYNDROME.pptx1236ygdsdfhjjhtgedsxNEPHROTIC SYNDROME.pptx1236ygdsdfhjjhtgedsx
NEPHROTIC SYNDROME.pptx1236ygdsdfhjjhtgedsxarvind339112
 
Acute decompensated heart failure
Acute decompensated heart failure Acute decompensated heart failure
Acute decompensated heart failure Dr. Armaan Singh
 
1. Nephrotic syndrome 01.04.15 lecture.pptx
1. Nephrotic syndrome 01.04.15 lecture.pptx1. Nephrotic syndrome 01.04.15 lecture.pptx
1. Nephrotic syndrome 01.04.15 lecture.pptxIvwananjisikombe1
 
Overview of management of nephrotic syndrom
Overview of management of nephrotic syndromOverview of management of nephrotic syndrom
Overview of management of nephrotic syndromOgechukwu Uzoamaka Mbanu
 
nephrotic syndrom and UTI
nephrotic syndrom and UTI nephrotic syndrom and UTI
nephrotic syndrom and UTI mimios
 
Nephrotic syndrome
Nephrotic syndromeNephrotic syndrome
Nephrotic syndromeSachin Verma
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic Syndromeedwinchowyw
 
Diabetic nephropathy management
Diabetic nephropathy managementDiabetic nephropathy management
Diabetic nephropathy managementNaresh Monigari
 
Nephrotic syndrome
Nephrotic syndrome Nephrotic syndrome
Nephrotic syndrome Abhay Mange
 

Similar to proteinuria approach Dr. Abdel Rahman Mansy.pdf (20)

IgA Nephropathy
IgA NephropathyIgA Nephropathy
IgA Nephropathy
 
NEPHROTIC SYNDROME
NEPHROTIC SYNDROMENEPHROTIC SYNDROME
NEPHROTIC SYNDROME
 
grand round 2.pptx
grand round 2.pptxgrand round 2.pptx
grand round 2.pptx
 
nephrotic syndrome final TREATMENT EVALUATION.ppt
nephrotic syndrome final TREATMENT EVALUATION.pptnephrotic syndrome final TREATMENT EVALUATION.ppt
nephrotic syndrome final TREATMENT EVALUATION.ppt
 
Generalized oedema & Proteinuria
Generalized oedema & ProteinuriaGeneralized oedema & Proteinuria
Generalized oedema & Proteinuria
 
Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...
Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...
Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...
 
Nephrotic and nephritic Syndrome children 7.ppt
Nephrotic and nephritic Syndrome children 7.pptNephrotic and nephritic Syndrome children 7.ppt
Nephrotic and nephritic Syndrome children 7.ppt
 
Nephrotic syndrome
Nephrotic syndrome Nephrotic syndrome
Nephrotic syndrome
 
NEPHROTIC SYNDROME.pptx1236ygdsdfhjjhtgedsx
NEPHROTIC SYNDROME.pptx1236ygdsdfhjjhtgedsxNEPHROTIC SYNDROME.pptx1236ygdsdfhjjhtgedsx
NEPHROTIC SYNDROME.pptx1236ygdsdfhjjhtgedsx
 
Acute decompensated heart failure
Acute decompensated heart failure Acute decompensated heart failure
Acute decompensated heart failure
 
1. Nephrotic syndrome 01.04.15 lecture.pptx
1. Nephrotic syndrome 01.04.15 lecture.pptx1. Nephrotic syndrome 01.04.15 lecture.pptx
1. Nephrotic syndrome 01.04.15 lecture.pptx
 
Overview of management of nephrotic syndrom
Overview of management of nephrotic syndromOverview of management of nephrotic syndrom
Overview of management of nephrotic syndrom
 
Anticoagulants.ppt
Anticoagulants.pptAnticoagulants.ppt
Anticoagulants.ppt
 
Nephrotic.pptx
Nephrotic.pptxNephrotic.pptx
Nephrotic.pptx
 
nephrotic syndrom and UTI
nephrotic syndrom and UTI nephrotic syndrom and UTI
nephrotic syndrom and UTI
 
Nephrotic syndrome
Nephrotic syndromeNephrotic syndrome
Nephrotic syndrome
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic Syndrome
 
Diabetic nephropathy management
Diabetic nephropathy managementDiabetic nephropathy management
Diabetic nephropathy management
 
Nephrotic syndrome
Nephrotic syndrome Nephrotic syndrome
Nephrotic syndrome
 
nephrotic syndrome.pptx
nephrotic syndrome.pptxnephrotic syndrome.pptx
nephrotic syndrome.pptx
 

More from Internal medicine department, faculty of Medicine Beni-Suef University Egypt

More from Internal medicine department, faculty of Medicine Beni-Suef University Egypt (20)

Urticarial vasculitis diagnostic challenge in 2 cases Ahmed Yehia, MD immunolgy
Urticarial vasculitis diagnostic challenge in 2 cases Ahmed Yehia, MD immunolgyUrticarial vasculitis diagnostic challenge in 2 cases Ahmed Yehia, MD immunolgy
Urticarial vasculitis diagnostic challenge in 2 cases Ahmed Yehia, MD immunolgy
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
The Catastrophe (Anaphylaxis ), Case based approach to guidelines Ahmed Yehia...
The Catastrophe (Anaphylaxis ), Case based approach to guidelines Ahmed Yehia...The Catastrophe (Anaphylaxis ), Case based approach to guidelines Ahmed Yehia...
The Catastrophe (Anaphylaxis ), Case based approach to guidelines Ahmed Yehia...
 
Holistic Approach to rheumatic patients Ahmed Yehia Ismaeel, Lecturer of inte...
Holistic Approach to rheumatic patients Ahmed Yehia Ismaeel, Lecturer of inte...Holistic Approach to rheumatic patients Ahmed Yehia Ismaeel, Lecturer of inte...
Holistic Approach to rheumatic patients Ahmed Yehia Ismaeel, Lecturer of inte...
 
Introduction to GN glomerulonephritis, case-based approach Ahmed Yehia lectur...
Introduction to GN glomerulonephritis, case-based approach Ahmed Yehia lectur...Introduction to GN glomerulonephritis, case-based approach Ahmed Yehia lectur...
Introduction to GN glomerulonephritis, case-based approach Ahmed Yehia lectur...
 
CKD MBD chronic kidney disease mineral bone disease Dr. Abdel Rahman Mansy
CKD MBD chronic kidney disease mineral bone disease Dr. Abdel Rahman MansyCKD MBD chronic kidney disease mineral bone disease Dr. Abdel Rahman Mansy
CKD MBD chronic kidney disease mineral bone disease Dr. Abdel Rahman Mansy
 
SLE Systemic lupus erythematosus basics 2022 Prof. Hanan Ali Taha
SLE Systemic lupus erythematosus basics 2022 Prof. Hanan Ali TahaSLE Systemic lupus erythematosus basics 2022 Prof. Hanan Ali Taha
SLE Systemic lupus erythematosus basics 2022 Prof. Hanan Ali Taha
 
Infective endocarditis ESC guidelines Ahmed Yehia. MD
Infective endocarditis ESC guidelines Ahmed Yehia. MDInfective endocarditis ESC guidelines Ahmed Yehia. MD
Infective endocarditis ESC guidelines Ahmed Yehia. MD
 
Pheochromocytoma, Dr. Mahmoud Naiem, internal medicine and endocrinology
Pheochromocytoma, Dr. Mahmoud Naiem, internal medicine and endocrinologyPheochromocytoma, Dr. Mahmoud Naiem, internal medicine and endocrinology
Pheochromocytoma, Dr. Mahmoud Naiem, internal medicine and endocrinology
 
Lupus nephritis update Ahmed Yehia
Lupus nephritis update Ahmed YehiaLupus nephritis update Ahmed Yehia
Lupus nephritis update Ahmed Yehia
 
Vitamin D trying to solve the dilemma Ahmed Yehia
Vitamin D trying to solve the dilemma Ahmed YehiaVitamin D trying to solve the dilemma Ahmed Yehia
Vitamin D trying to solve the dilemma Ahmed Yehia
 
Familial Mediterranean fever guidelines, case based, Ahmed Yehia
Familial Mediterranean fever guidelines, case based,  Ahmed YehiaFamilial Mediterranean fever guidelines, case based,  Ahmed Yehia
Familial Mediterranean fever guidelines, case based, Ahmed Yehia
 
Swelling..swelling ( angioedema approach ) Ahmed Yehia, MD internal medicine,...
Swelling..swelling ( angioedema approach ) Ahmed Yehia, MD internal medicine,...Swelling..swelling ( angioedema approach ) Ahmed Yehia, MD internal medicine,...
Swelling..swelling ( angioedema approach ) Ahmed Yehia, MD internal medicine,...
 
Approach to musculoskeletal pain ahmed yehia Ismaeel, MD
Approach to musculoskeletal pain ahmed yehia Ismaeel, MDApproach to musculoskeletal pain ahmed yehia Ismaeel, MD
Approach to musculoskeletal pain ahmed yehia Ismaeel, MD
 
Rheumatoid arthritis Dr. Lamiaa Mohammed
Rheumatoid arthritis Dr. Lamiaa MohammedRheumatoid arthritis Dr. Lamiaa Mohammed
Rheumatoid arthritis Dr. Lamiaa Mohammed
 

Recently uploaded

CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumassuser144901
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryDr Simran Deepak Vangani
 
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.GawadHemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.GawadNephroTube - Dr.Gawad
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)Monika Kanwar
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionGolden Helix
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthCatherine Liao
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxdrtabassum4
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptdesktoppc
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationMedicoseAcademics
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerSherrylee83
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...PhRMA
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answersShafnaP5
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAkashGanganePatil1
 
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...marcuskenyatta275
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesTina Purnat
 
PREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptxPREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptxPupayumnam1
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadNephroTube - Dr.Gawad
 
Pharmacology of drugs acting on Renal System.pdf
Pharmacology of drugs acting on Renal System.pdfPharmacology of drugs acting on Renal System.pdf
Pharmacology of drugs acting on Renal System.pdfAFFIFA HUSSAIN
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghanahealthwatchghana
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Catherine Liao
 

Recently uploaded (20)

CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic trauma
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.GawadHemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial health
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 ppt
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulation
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
 
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
PREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptxPREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptx
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
 
Pharmacology of drugs acting on Renal System.pdf
Pharmacology of drugs acting on Renal System.pdfPharmacology of drugs acting on Renal System.pdf
Pharmacology of drugs acting on Renal System.pdf
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
 

proteinuria approach Dr. Abdel Rahman Mansy.pdf

  • 1. by
  • 3. Male patient 49 y old , DM 5 years ago controlled on insulin , not HTN, labs of routine follow up 24 hour urinary protein 120 mg /d. what`s the best choice ? 1. Add ACEI 2. Protein restriction 3. Follow up after 3 months 4. Assess proteinuria e different method
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13. GN presentation GN PRESENTING WITH NEPHROTIC SYNDROME Minimal change GN Membranous GN Focal segmental GN (FSGN) Amyloidosis Diabetic nephropathy GN PRESENTING WITH NEPHRITIC SYNDROME Diffuse proliferative GN Rapidly progressive GN (RPGN) GN WITH NEPHROTIC SYNDROME or NEPHRITIC SYNDROME or MIXED NEPHROTIC/NEPHRITIC Membranoproliferative GN Mesangioproliferative GN
  • 14.
  • 15. Nephritic syndrome A disease characterized by acute onset of : Proteinuria (sub nephrotic) Hematuria… dysmorphic RBCs,RBCs cast Oliguria Hypertension Odema
  • 16. GN presentation GN PRESENTING WITH NEPHROTIC SYNDROME Minimal change GN Membranous GN Focal segmental GN (FSGN) Amyloidosis Diabetic nephropathy GN PRESENTING WITH NEPHRITIC SYNDROME Diffuse proliferative GN Rapidly progressive GN (RPGN) GN WITH NEPHROTIC SYNDROME or NEPHRITIC SYNDROME or MIXED NEPHROTIC/NEPHRITIC Membranoproliferative GN Mesangioproliferative GN
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 30.
  • 31.
  • 33.
  • 34.
  • 35. ACEi and/or ARBs lower GFR, and a 10%–20% increase in SCr is often observed. Unless creatinine continues to rise, this moderate increase reflects their effect on kidney hemodynamics and not worsening intrinsic kidney disease, and should not prompt withdrawal of the medication
  • 36. If the patient is unable to tolerate an ACEi or ARB a direct renin inhibitor (DRI) or mineralocorticoid receptor antagonist (MRA) can be used
  • 37. unable to tolerate even low-dose ACEi, ARB, MRA, or DRI. antihypertensive agents are recommended for both control of BP and improvement in urine protein excretion. &Non dihydropyridine (CCB), such as diltiazem and verapamil, modestly reduce proteinuria. &Beta blockers, diuretics, and a-1 blockers also reduce proteinuria, but to a lesser degree. &Dihydropyridine CCB and methyldopa have little impact on proteinuria and may even increase proteinuria.
  • 38.
  • 41.
  • 42.
  • 43. Can use NOAC or not in NS?
  • 45. Female patient 48 y old, HTN on bisoprolol 5mg ,presented e lower limb edema and poly arthropathy labs : 24 h urinary protein 1.8 g/d serum albumin 3.6 ANA 1/80 C3,C4 :normal virology : -ve Renal biopsy done
  • 46.
  • 47. NB: F/u ANA in diff lab ANA less than 1/40 What`s the next step? 1- start steroid 2- start steroid and cyclosporine 3- supportive TTT { ACEI,…}e f/u ptnuria.albumin 4- follow up after 3 months
  • 49. NB: F/u ANA in diff lab ANA less than 1/40 What`s the next step? 1- start steroid 2- start steroid and cyclosporine 3- supportive TTT { ACEI,…}e f/u ptnuria.albumin 4- follow up after 3 months
  • 50.
  • 52.
  • 54.
  • 55.